Technical Analysis for MORF - Morphic Holding, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Golden Cross | Bullish | 0.00% | |
Slingshot Bullish | Bullish Swing Setup | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Overbought Stochastic | Strength | 0.00% | |
New Uptrend | Bullish | -4.46% | |
Pocket Pivot | Bullish Swing Setup | -4.46% | |
Volume Surge | Other | -4.46% | |
NR7 | Range Contraction | -4.46% | |
Wide Bands | Range Expansion | -4.46% | |
Gapped Up | Strength | -4.46% |
Alert | Time |
---|---|
Down 1 ATR | about 8 hours ago |
Down 5% | about 8 hours ago |
Down 3% | about 9 hours ago |
Fell Below Previous Day's Low | about 9 hours ago |
60 Minute Opening Range Breakdown | about 9 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/01/2024
Morphic Holding, Inc., a biopharmaceutical company, focuses on the discovery and development of oral small-molecule integrin therapeutics. The company's lead product candidates in clinical development are MORF-720, a selective oral avb6 specific integrin inhibitor for the treatment of idiopathic pulmonary fibrosis; and a4b7 specific integrin inhibitors for the treatment of inflammatory bowel disease. Its product candidates in discovery stage include an avb1 integrin for the treatment of fibrosis; two TGF-b activations for gastrointestinal cancers and fibrosis; and other aI domain integrins. The company was founded in 2014 and is headquartered in Waltham, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Clinical Development Molecular Biology Gastrointestinal Inflammatory Bowel Disease Idiopathic Pulmonary Fibrosis Pulmonary Fibrosis Fibrosis Gastrointestinal Cancer Treatment Of Fibrosis Treatment Of Idiopathic Pulmonary Fibrosis Treatment Of Inflammatory Bowel Disease Integrin
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Clinical Development Molecular Biology Gastrointestinal Inflammatory Bowel Disease Idiopathic Pulmonary Fibrosis Pulmonary Fibrosis Fibrosis Gastrointestinal Cancer Treatment Of Fibrosis Treatment Of Idiopathic Pulmonary Fibrosis Treatment Of Inflammatory Bowel Disease Integrin
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 62.08 |
52 Week Low | 19.345 |
Average Volume | 553,917 |
200-Day Moving Average | 29.55 |
50-Day Moving Average | 29.59 |
20-Day Moving Average | 30.12 |
10-Day Moving Average | 30.63 |
Average True Range | 2.01 |
RSI (14) | 57.26 |
ADX | 25.64 |
+DI | 32.37 |
-DI | 16.94 |
Chandelier Exit (Long, 3 ATRs) | 28.68 |
Chandelier Exit (Short, 3 ATRs) | 31.27 |
Upper Bollinger Bands | 35.28 |
Lower Bollinger Band | 24.97 |
Percent B (%b) | 0.74 |
BandWidth | 34.23 |
MACD Line | 0.86 |
MACD Signal Line | 0.25 |
MACD Histogram | 0.6087 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 36.74 | ||||
Resistance 3 (R3) | 36.95 | 35.77 | 36.04 | ||
Resistance 2 (R2) | 35.77 | 34.70 | 35.66 | 35.80 | |
Resistance 1 (R1) | 34.16 | 34.05 | 33.57 | 33.95 | 35.57 |
Pivot Point | 32.98 | 32.98 | 32.69 | 32.87 | 32.98 |
Support 1 (S1) | 31.37 | 31.91 | 30.78 | 31.16 | 29.53 |
Support 2 (S2) | 30.19 | 31.26 | 30.08 | 29.30 | |
Support 3 (S3) | 28.58 | 30.19 | 29.06 | ||
Support 4 (S4) | 28.37 |